The UK’s NICE approved reimbursement for Genmab’s tisotumab vedotin (Tivdak) for advanced cervical cancer, reversing earlier cost-effectiveness concerns from the spring. NICE’s updated position follows MHRA authorization based on the Phase 3 trial NCT04697628. In the Phase 3 data set of more than 500 patients, Tivdak improved survival and delayed progression versus chemotherapy in recurrent or metastatic settings after prior systemic therapy. NICE cited economic modeling uncertainties at draft guidance but said a confidential discount with NHS England mitigated earlier issues. The reimbursement decision reduces payer friction around a targeted antibody-drug conjugate option that had been narrowly positioned due to cost hurdles. It also clarifies the path for NHS uptake if final guidance is implemented. The NICE move is a reminder that even with positive clinical evidence, pricing and modeling assumptions can determine whether ADCs reach routine practice in the U.K. market.